title: Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index.
abstract: Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CDKIs). p27KIP1, which has a high degree of similarity with p21WAF1, is a general CDKI thought to be involved in G1 arrest in response to agents that inhibit cell cycle progression. The aims of this study were 1) to establish the pattern of expression of p27KIP1 protein in nontumor lymphoid tissue, 2) to determine whether p27KIP1 is involved in lymphomagenesis, and 3) to address the possible relationship between p27KIP1 and p21WAF1 expression in reactive and tumor lymphoid tissue. p27KIP1 protein was found to be mainly present in quiescent lymphocytes in reactive lymphoid tissue as well as in peripheral blood lymphocytes, with an inverse expression for p27KIP1 and Ki-67 proteins. The same p27KIP1 expression pattern was observed in lymphomas, independently of histological type; small resting cells were p27KIP1 positive, and large proliferating cells were p27KIP1 negative. Therefore, tumors with a low proliferative index were mostly positive, whereas tumors characterized by a higher growth fraction bad low p27KIP1 protein levels. An unexpected finding was the existence of a group of six cases of high-grade lymphomas (three diffuse large B-cell lymphomas and three Burkitt's lymphomas) with homogeneously strong staining for p27KIP1 protein. All 6 of these cases belong to a group of 28 cases characterized by blockage of the p53 tumor suppressor pathway, as determined by genetic (p53 mutation) or immunophenotypic studies (p53+/p21-). p27KIP1 expression was not seen in any case of aggressive non-Hodgkin's lymphoma with an intact p53 pathway. The results indicate that p27KIP1 is down-regulated in lymphomas with a high proliferative index, although it is highly expressed in high-grade lymphomas with defects in the p53 pathway.
authors.affiliation: Department of Pathology, Virgen de la Salud Hospital, Toledo, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Sánchez-Beato
authors.forename: A I
authors.initials: AI
authors.lastname: Sáez
authors.forename: J C
authors.initials: JC
authors.lastname: Martínez-Montero
authors.forename: M
authors.initials: M
authors.lastname: Sol Mateo
authors.forename: L
authors.initials: L
authors.lastname: Sánchez-Verde
authors.forename: R
authors.initials: R
authors.lastname: Villuendas
authors.forename: G
authors.initials: G
authors.lastname: Troncone
authors.forename: M A
authors.initials: MA
authors.lastname: Piris
mesh_terms: D018797:Cell Cycle Proteins; D002455:Cell Division; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D006689:Hodgkin Disease / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008221:Lymphoid Tissue / Q000378:metabolism* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000473:pathology; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D019310:Pseudolymphoma / Q000378:metabolism / Q000473:pathology; D025521:Tumor Suppressor Proteins
chemical_list: D018797:Cell Cycle Proteins; D008869:Microtubule-Associated Proteins; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases